generics Raúl Díaz-Varela is the CEO of Kern Pharma and has served as president of Spain’s generics association AESEG since 2008. He speaks to us about the challenges facing generic companies, and Kern Pharma’s own strategies for growth through in-licensing and local partnerships in Europe and Latin America. What are your…
clinical trials Ciro Caravaggio, General Manager at Roche Chile discusses Roche’s mission as a highly specialized biotech with a long presence in Chile. He stresses the importance of the affiliate’s role in clinical trials and the key to success in the Chilean pharmaceutical market. M. Caravaggio, you arrived at the helm of…
logistics Raúl Sánchez, general manager of Peri Logistics speaks about the main features that distinguish Peri Logistics as a pharmaceutical logistics operator. Celebrating its 10th year anniversary this year, the company has obtained the ISO 9001:2008, an international standard related to quality management system. Peri Logistics invested in the technologies to…
Internationalization The history of AmCham Spain dates back to 1917 and has a critical part of developing bilateral relations between Spain and the United States. The company’s president, Jaime Malet, discusses AmCham Spain’s ongoing efforts to attract investment by American companies in Spain today. What are AmCham’s greatest challenges today? The…
Biotechnology Merck’s managing director discusses the importance of diversification to succeed in Poland by saying: “Nowadays, in such a dynamic environment the healthy level of diversification that Merck offers is becoming a critical factor for sustainable growth.” Despite the fact that the Polish business environment has changed significantly, access to innovation…
market access Medtronic’s country director brings some interesting perspectives on the differences between the pharma and medical device regulations in Poland by saying: “the medical device industry is discriminated against, as we do not have clear indications to obtain product reimbursement.” Nonetheless, he adds: “The medical device industry in Poland is predictable…
Generics The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the positive and negative aspects of the new legislative framework implemented in January 2012? The positive aspects of the Reimbursement Act…
diabetes PMG Pharma, a niche player, with products concentrated in the nephrology/dialysis, injectables and diabetes areas, has concluded distribution agreements with companies from all over the world. “Many are underestimating the Chinese pharmaceutical market but I expect to see a lot of business coming from that country”, tells Horst Peter Endler…
recession Dr. Heitor Costa, Executive Director at Apifarm, Portugal, discusses the country’s economic situation and the presence of international pharmaceutical companies despite the recession. He further discusses the current policy and influence of generics on the pharmaceutical industry, and why he feels investment in Portugal is so crucial at a time…
Pharmaceutical Industry Baxter Spain’s general manager, Luigi Antoniazzi, discusses the challenges that the affiliate has faced in light of recent changes in the market, and the strategies taken to adapt to an ever-changing ecosystem for the pharmaceutical industry in the country. You became general manager of Baxter Spain & Portugal in 2011,…
See our Cookie Privacy Policy Here